Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes

A systematic review

Rohit Kedia, Supriya Kulkarni, Meredith Ross, Vijay Shivaswamy

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The dramatic rise in the prevalence of obesity and diabetes is associated with increased morbidity, mortality, and public health care costs worldwide. The need for new, effective, and long-lasting drugs is urgent. Recent research has focused on the role of the inhibitors of sodium-glucose co-transporter 2 (SGLT-2). Clinical trials have shown that SGLT-2 inhibitors have glycemic efficacy and weight-lowering potential. Dual drug therapy is a recommended therapy for patients with new-onset type 2 diabetes who need significant glycemic control. Fixed-dose combination therapy represents a particularly attractive option as it may reduce pill burden and improve adherence. The combination of metformin and empagliflozin was approved by the US Food and Drug Administration in 2014 and represents a safe and effective means to combat glycemic control and weight gain. The purpose of this systematic review is to summarize the background of the SGLT-2 inhibitors, particularly empagliflozin, and focus on the safety and efficacy of the fixed-dose combination of empagliflozin and metformin.

Original languageEnglish (US)
Pages (from-to)1999-2006
Number of pages8
JournalPatient Preference and Adherence
Volume10
DOIs
StatePublished - Sep 30 2016

Fingerprint

Sodium-Glucose Transporter 2
Symporters
Metformin
Type 2 Diabetes Mellitus
chronic illness
drug
United States Food and Drug Administration
Health Care Costs
morbidity
Weight Gain
Therapeutics
mortality
Public Health
Obesity
public health
Clinical Trials
health care
Morbidity
Safety
Weights and Measures

Keywords

  • Diabetes mellitus
  • Empagliflozin
  • Hyperglycemia
  • Metformin
  • Systematic review

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Social Sciences (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy

Cite this

Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes : A systematic review. / Kedia, Rohit; Kulkarni, Supriya; Ross, Meredith; Shivaswamy, Vijay.

In: Patient Preference and Adherence, Vol. 10, 30.09.2016, p. 1999-2006.

Research output: Contribution to journalReview article

@article{04ff6ff6baa443cfacfeab0fe7a71123,
title = "Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: A systematic review",
abstract = "The dramatic rise in the prevalence of obesity and diabetes is associated with increased morbidity, mortality, and public health care costs worldwide. The need for new, effective, and long-lasting drugs is urgent. Recent research has focused on the role of the inhibitors of sodium-glucose co-transporter 2 (SGLT-2). Clinical trials have shown that SGLT-2 inhibitors have glycemic efficacy and weight-lowering potential. Dual drug therapy is a recommended therapy for patients with new-onset type 2 diabetes who need significant glycemic control. Fixed-dose combination therapy represents a particularly attractive option as it may reduce pill burden and improve adherence. The combination of metformin and empagliflozin was approved by the US Food and Drug Administration in 2014 and represents a safe and effective means to combat glycemic control and weight gain. The purpose of this systematic review is to summarize the background of the SGLT-2 inhibitors, particularly empagliflozin, and focus on the safety and efficacy of the fixed-dose combination of empagliflozin and metformin.",
keywords = "Diabetes mellitus, Empagliflozin, Hyperglycemia, Metformin, Systematic review",
author = "Rohit Kedia and Supriya Kulkarni and Meredith Ross and Vijay Shivaswamy",
year = "2016",
month = "9",
day = "30",
doi = "10.2147/PPA.S85748",
language = "English (US)",
volume = "10",
pages = "1999--2006",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes

T2 - A systematic review

AU - Kedia, Rohit

AU - Kulkarni, Supriya

AU - Ross, Meredith

AU - Shivaswamy, Vijay

PY - 2016/9/30

Y1 - 2016/9/30

N2 - The dramatic rise in the prevalence of obesity and diabetes is associated with increased morbidity, mortality, and public health care costs worldwide. The need for new, effective, and long-lasting drugs is urgent. Recent research has focused on the role of the inhibitors of sodium-glucose co-transporter 2 (SGLT-2). Clinical trials have shown that SGLT-2 inhibitors have glycemic efficacy and weight-lowering potential. Dual drug therapy is a recommended therapy for patients with new-onset type 2 diabetes who need significant glycemic control. Fixed-dose combination therapy represents a particularly attractive option as it may reduce pill burden and improve adherence. The combination of metformin and empagliflozin was approved by the US Food and Drug Administration in 2014 and represents a safe and effective means to combat glycemic control and weight gain. The purpose of this systematic review is to summarize the background of the SGLT-2 inhibitors, particularly empagliflozin, and focus on the safety and efficacy of the fixed-dose combination of empagliflozin and metformin.

AB - The dramatic rise in the prevalence of obesity and diabetes is associated with increased morbidity, mortality, and public health care costs worldwide. The need for new, effective, and long-lasting drugs is urgent. Recent research has focused on the role of the inhibitors of sodium-glucose co-transporter 2 (SGLT-2). Clinical trials have shown that SGLT-2 inhibitors have glycemic efficacy and weight-lowering potential. Dual drug therapy is a recommended therapy for patients with new-onset type 2 diabetes who need significant glycemic control. Fixed-dose combination therapy represents a particularly attractive option as it may reduce pill burden and improve adherence. The combination of metformin and empagliflozin was approved by the US Food and Drug Administration in 2014 and represents a safe and effective means to combat glycemic control and weight gain. The purpose of this systematic review is to summarize the background of the SGLT-2 inhibitors, particularly empagliflozin, and focus on the safety and efficacy of the fixed-dose combination of empagliflozin and metformin.

KW - Diabetes mellitus

KW - Empagliflozin

KW - Hyperglycemia

KW - Metformin

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=84992699335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992699335&partnerID=8YFLogxK

U2 - 10.2147/PPA.S85748

DO - 10.2147/PPA.S85748

M3 - Review article

VL - 10

SP - 1999

EP - 2006

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -